Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel M D Tucker

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Primary Care Diabetes|November 13, 2010
The cost-effectiveness of interventions in diabetes: a review of published economic evaluations in the UK setting, with an eye on the futureDaniel M D Tucker, Andrew J Palmer
Current Medical Research and Opinion|April 1, 2006
Counting the costs of overweight and obesity: modeling clinical and cost outcomesDaniel M D Tucker, Andrew J Palmer, William J Valentine, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 28, 2005
Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studiesAndrew J Palmer, Daniel M D Tucker, William J Valentine, et al.
Diabetes Care|April 30, 2008
Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 studyPeter Gaede, William J Valentine, Andrew J Palmer, et al.
Current Medical Research and Opinion|March 16, 2007
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomesJoshua A Ray, Kristina S Boye, Nicole Yurgin, et al.
Current Medical Research and Opinion|November 2, 2006
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertensionAndrew J Palmer, William J Valentine, Daniel M D Tucker, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Primary Care Diabetes|November 13, 2010
The cost-effectiveness of interventions in diabetes: a review of published economic evaluations in the UK setting, with an eye on the futureDaniel M D Tucker, Andrew J Palmer
Current Medical Research and Opinion|April 1, 2006
Counting the costs of overweight and obesity: modeling clinical and cost outcomesDaniel M D Tucker, Andrew J Palmer, William J Valentine, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|April 28, 2005
Cost-effectiveness of irbesartan in diabetic nephropathy: a systematic review of published studiesAndrew J Palmer, Daniel M D Tucker, William J Valentine, et al.
Diabetes Care|April 30, 2008
Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 studyPeter Gaede, William J Valentine, Andrew J Palmer, et al.
Current Medical Research and Opinion|March 16, 2007
Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomesJoshua A Ray, Kristina S Boye, Nicole Yurgin, et al.
Current Medical Research and Opinion|November 2, 2006
A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertensionAndrew J Palmer, William J Valentine, Daniel M D Tucker, et al.
Pageof 1